REGENXBIO partners with Nippon Shinyaku for MPS therapies

[ad_1]

Hand Holding a Chemical Solution Test-tube in a bio-Chemistry DNA Research Laboratory

YinYang

REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO’s gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS II, and RGX-111 for Hurler syndrome, or MPS I.

Under the deal, REGENXBIO (

[ad_2]

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *